NASDAQ: NRXP
Nrx Pharmaceuticals Inc Stock Ownership - Who owns Nrx Pharmaceuticals?

Insider buying vs selling

Have Nrx Pharmaceuticals Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Jonathan C. JavittChairman and Chief Scientist2024-12-1740,000$1.17
$46.80kBuy

1 of 1

NRXP insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when NRXP insiders and whales buy or sell their stock.

NRXP Shareholders

What type of owners hold Nrx Pharmaceuticals Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Daniel C. Javitt136.54%23,606,657$77.19MInsider
Jonathan C. Javitt92.46%15,985,163$52.27MInsider
Chaim Hurvitz14.02%2,423,236$7.92MInsider
Brac Lending Group LLC12.89%2,228,435$7.29MInsider
Anson Funds Management LP6.82%1,179,061$3.86MInstitution
Polar Asset Management Partners Inc5.82%1,005,536$3.29MInsider
Big Rock Partners Sponsor LLC3.00%519,315$1.70MInsider
Patrick John Flynn2.34%404,291$1.32MInsider
Vanguard Group Inc2.25%388,925$1.27MInstitution
Advisorshares Investments LLC1.66%286,797$937.83kInstitution

1 of 3

NRXP vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
NRXP4.61%95.39%Net Buying
SNTI18.72%81.28%Net Buying
MAIA4.87%16.62%Net BuyingNet Buying
FBIO16.61%50.90%Net Buying
ATRA17.07%82.93%Net BuyingNet Buying

Nrx Pharmaceuticals Stock Ownership FAQ

Who owns Nrx Pharmaceuticals?

Nrx Pharmaceuticals (NASDAQ: NRXP) is owned by 13.07% institutional shareholders, 270.70% Nrx Pharmaceuticals insiders, and 0.00% retail investors. Daniel C. Javitt is the largest individual Nrx Pharmaceuticals shareholder, owning 23.61M shares representing 136.54% of the company. Daniel C. Javitt's Nrx Pharmaceuticals shares are currently valued at $75.78M.

If you're new to stock investing, here's how to buy Nrx Pharmaceuticals stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.